Investors / Germany / 415 Capital
415 Capital
Venture capital · Munich, Germany · Europe
415 Capital is a specialist venture capital firm that invests in medical technology companies addressing large unmet patient needs in chronic diseases, with an emphasis on cardiovascular and neurovascular disorders. It provides capital, clinical and regulatory expertise, and commercial market access to its portfolio companies.
Invests inHealthcare & Biotech
In its own wordsmedical technologycardiovascularneurovascularstructural heartmedical deviceshealthcare
Your fit with 415 Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fits415 Capital lists 17 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Series A, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in United States. It invests most often alongside Unorthodox Ventures, AMED Ventures and NEA.
Counts come from funding rounds that name 415 Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not 415 Capital's whole history. Rounds on record name 3 companies; its own site lists 17. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first round415 Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 33% |
| Series B | 33% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 0 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 44th | 17 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 89th | 18% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Unorthodox Ventures | 3 |
| AMED Ventures | 2 |
| NEA | 2 |
| Panakes Partners | 2 |
| Santé Ventures | 2 |
| Wellington Partners | 2 |
| Bain Capital Ventures | 1 |
| BlueOcean Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1694%
- No longer answers00%
- Points to another company16%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Unorthodox Ventures
Compare 415 Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with 415 Capital| Date | Company | Stage |
|---|---|---|
| 15 Sept 2026 | Series A | |
| 7 Apr 2026 | Series C+ | |
| 10 Sept 2024 | Series B |
Round details for 415 Capital
Amounts, full round histories and every co-investor in 415 Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
17 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| ACIST Medical Systems provides diagnostic technologies that deliver the power to visualize, assess and improve patient treatment. | Healthcare & Biotech | Portfolio page | ||
| Boston Heart Diagnostics is transforming the treatment of cardiovascular disease and related diseases with novel diagnostics, reports, and a personalized, scientifically designed nutrition and lifestyle program | Healthcare & Biotech | Portfolio page | ||
| Cardiac Success pioneers an innovative transcatheter procedure to treat heart failure patients by directly reshaping the ventricle | Healthcare & Biotech | Portfolio page | ||
| Corflow develops solutions for detecting and treating microvascular disease, specifically microvascular obstruction in heart attack patients. | Healthcare & Biotech | Sept 2024Series B | Page + round | |
| The company specializes in introducing and distributing high-quality and innovative medical products in the fields of cardiology, vascular and heart surgery through minimally invasive procedures. | Healthcare & Biotech | Portfolio page | ||
| Distalmotion develops and provides a robotic surgery system called DEXTER | Healthcare & Biotech | Portfolio page | ||
| The company manufactures and provides vascular and endovascular therapies and devices | Healthcare & Biotech | Portfolio page | ||
| Endovascular Engineering develops medical devices for removing blood clots | Healthcare & Biotech | Apr 2026Series C+ | Page + round | |
| Hilo provides a system for continuous blood pressure monitoring | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Laza Medical is developing an intelligent imaging system to simplify cardiac procedures | Healthcare & Biotech | Portfolio page | ||
| R 3 Vascular makes scaffolds using a proprietary manufacturing process from a unique bioresorbable polymer. | Healthcare & Biotech | Portfolio page | ||
| Recor Medical develops and sells a system for renal denervation to treat high blood pressure | Healthcare & Biotech | Portfolio page | ||
| ReEmerge develops a therapy to restore cognitive function in people with traumatic brain injury | Healthcare & Biotech | Sept 2026Series A | Page + round | |
| Supira Medical is developing a next-generation percutaneous ventricular assist device for use in high-risk patients undergoing interventional procedures or experiencing cardiogenic shock. | Healthcare & Biotech | Portfolio page | ||
| TRiCares develops a catheter-based tricuspid valve replacement system for treating tricuspid regurgitation | Healthcare & Biotech | Portfolio page | ||
| Vesper Medical develops and sells medical devices, including venous stent systems, to treat deep venous disease. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- 415capital.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 10 Sept 2024
- Companies checked
- 17
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get 415 Capital's profile as data
Pull 415 Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/415capital.com
# also
GET /v1/firms/415capital.com/portfolio
GET /v1/firms/415capital.com/coinvestors
GET /v1/firms/415capital.com/news